AKT1 and endometrial cancer: NLRC5 promotes AN3CA cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer; however, it can be inhibited by LY294002, a specific inhibitor of the PI3K/AKT signaling pathway (53).